PTC Therapeutics, Inc. (PTCT) on Decifer

Decifer ranks PTCT number 82 of 277 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 37% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 115% a year, profits grew 281% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• We do not have a clean read on how it is run yet.
• Our durability check found pressure on this name, which costs it a few points.
• Its profit margin and growth are both unusually high right now compared to its own history, the kind of combination that often fades once conditions normalize.
• Explosive revenue up about 115% and profits up 281% with strong 37% returns are eye catching, but no worldview role, an unclear read on management, and durability pressure argue the surge may not last.

The current read

The evidence on PTCT lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Healthcare, Biotech & Devices: PTC Therapeutics, Inc. operates in biotechnology. That places it inside the Healthcare, Biotech & Devices story.

Read the full PTCT research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.